Search | Clinical Trials Finder

Conditions: Hepatitis B
Interventions: INO-1800, INO-9112, Nucleos(t)ide Analogue Treatment; Biological · Drug
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 7
States / cities: San Diego, California • Miami, Florida • Manhasset, New York + 4 more

Conditions: HIV Infections
Interventions: VRC-HIVDNA009-00-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 14
States / cities: Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 8 more

Conditions: Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma, Peritoneal Carcinomatosis
Interventions: DC vaccine, Celecoxib, Interferon Alfa-2b, rintatolimod; Biological · Drug
Lead sponsor: David Bartlett; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV-1-infection
Interventions: PENNVAX-GP, INO-6145, INO-9012, CELLECTRA® 2000; Biological · Device
Lead sponsor: Steven Deeks; Other
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: HIV Infections
Interventions: HIV-1 gag DNA, HIV-1 gag DNA plus IL-12 DNA adjuvant, CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine), Sodium chloride injection (0.9%); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2008
U.S. locations: 3
States / cities: Birmingham, Alabama • Baltimore, Maryland • Nashville, Tennessee

Conditions: HPV Infection
Interventions: pBI-11 (3 doses), pBI-11 (1 dose), Placebo (2 doses); Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Birmingham, Alabama • Baltimore, Maryland

Conditions: Melanoma (Skin), Intraocular Melanoma
Interventions: Xenogeneic Tyrosinase DNA Vaccine, TriGrid Delivery System for Intramuscular Electroporation; Biological · Device
Lead sponsor: Ichor Medical Systems Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: VRC-HIVDNA-016-00-VP, VRCHIVADV014-00-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV Infections
Interventions: PennVax B, IL-12, IL-15; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 8
States / cities: Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 4 more

Conditions: Plasmodium Falciparum Malaria
Interventions: Placebo, EP-1300; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Metastatic Colorectal Cancer
Interventions: Retifanlimab, Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform, N-803, SX-682; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza A Virus, H1N1 Subtype, Novel Swine-Origin
Interventions: VRC-FLUDNA057-00-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Herpes Genitalis
Interventions: VCL-HB01, Phosphate-buffered saline; Biological · Other
Lead sponsor: Vical; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 261 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 15
States / cities: Birmingham, Alabama • San Diego, California • Hollywood, Florida + 12 more

Conditions: Prostate Cancer, Bladder Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Sarcoma
Interventions: NY-ESO-1 Plasmid DNA Cancer Vaccine; Biological
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Conditions: Covid19
Interventions: SARS-CoV-2 mRNA vaccine; Biological
Lead sponsor: TruDiagnostic; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Malaria
Interventions: D/ChAd63-CA, D/ChAd63-CAT, Infectivity Control (IC) Group; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 50 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Bethesda, Maryland • Silver Spring, Maryland

Conditions: HIV Infections
Interventions: HIV-1 nef/tat/vif, env pDNA vaccine, rVSV HIV envC vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Cleveland, Ohio • Philadelphia, Pennsylvania

Conditions: Melanoma
Interventions: DC Vaccine + IFN, AdVTMM2/DC Vaccination; Biological
Lead sponsor: Lisa H. Butterfield, Ph.D.; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Melanoma
Interventions: injection of mouse TYRP2 DNA; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 7 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Acquired Immunodeficiency Syndrome, HIV Infection
Interventions: APL 400-003; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: EP HIV-1090; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Recombinant Granulocyte-Macrophage Colony-Stimulating Factor, Biospecimen Collection; Biological · Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, TNBC - Triple-Negative Breast Cancer, Triple-negative Breast Carcinoma
Interventions: Durvalumab, Neoantigen DNA vaccine, TDS-IM system (Inchor Medical Systems), Peripheral blood draw; Drug · Biological · Device + 1 more
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: HIV Infections
Interventions: APL 400-047, Bupivacaine hydrochloride; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2001
U.S. locations: 4
States / cities: Birmingham, Alabama • Rochester, New York • Nashville, Tennessee + 1 more

Search by objective public record fields.

Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects

Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies

Therapeutic Vaccination in Treated HIV Disease

Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults

Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+

Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation

Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals

Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults

EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

VRC 308: An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years Old

Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine

NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine

Methylation Effects of COV-19 Infection and Vaccinations

Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults

Evaluating the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy, HIV-Uninfected Adults

Multiple Antigen-Engineered DC Vaccine for Melanoma

Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune Response

Phase I Study of APL 400-003, a Candidate HIV Vaccine, in HIV-Negative Volunteers

Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected Patients

A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden

Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy

A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers